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Introduction
Rheumatic disease and kidney disease are both common 
in the general population. Rheumatologists are thus 
frequently exposed to patients with concomitant renal 
disease. In fact, 18% of rheumatology clinic patients were 
reported to have a glomerular ﬁ  ltration rate (GFR) of 
60 ml/minute or less as compared with the 5% reported 
within the general population [1]. When patients present 
with both, arthritis and kidney disease, the following 
questions have to be addressed. Is kidney disease a 
compli  cation of rheumatic disease or its management, or 
are they both manifestations of a single systemic auto-
immune disease? Is rheumatic disease a complication of 
kidney disease and its management? How do rheumatic 
disease and kidney disease aﬀ  ect each other even when 
they are unrelated? Th  e present review addresses these 
questions and may help attending specialists, either 
rheumatologists or nephrologists, to manage patients 
with concomitant rheumatic disease and kidney disease.
How to diagnose and monitor renal co-morbidity?
Renal co-morbidity may not be apparent in terms of signs 
and symptoms, so functional parameters must be routinely 
measured. Serum creatinine is the most commonly used 
parameter for renal excretory function and is therefore 
used to predict the GFR; for example, by applying the 
Modiﬁ  cation of Diet in Renal Disease formula. Nowa-
days, the estimated GFR deﬁ   nes the stage of chronic 
kidney disease (CKD) and most laboratories routinely 
report the estimated GFR along with serum creatinine 
results [2]. Th  e Modiﬁ  cation of Diet in Renal Disease 
formula as well as other formulas used for GFR predic-
tion, however, have not been validated to reliably predict 
GFR in patients with rheumatic diseases. In fact, the 
Modiﬁ   cation of Diet in Renal Disease formula may 
under  estimate renal function in patients with rheumatoid 
arthritis (RA) [3,4] or with lupus nephritis [5]. Conco-
mitant elevations of blood urea nitrogen and uric acid 
imply renal excretory failure but only at an advanced 
stage of kidney damage.
Excretion is only one of the many renal functions 
(Table 1), and the aforementioned parameters can fail to 
indicate serious and potentially fatal kidney disease. For 
example, serum parameters may not indicate damage to 
the glomerular ﬁ   ltration barrier, which only becomes 
evident on urinalysis. Proteinuria and hematuria, as 
detected by urine dipstick analysis, is suggestive of 
glomerulonephritis (GN) – in systemic lupus erythe  ma-
tosus (SLE) or anti-neutrophil cytoplasmic antibody 
(ANCA) vasculitis, for example – and massive protein-
uria is a hallmark of membranous lupus nephritis, 
amyloid-A amyloidosis or certain drug toxicities (Table 2). 
Dipstick urinalysis is routinely performed during the 
initial evalu  ation and monitoring visits by most rheuma-
tologists [6], although their lack of accuracy to detect 
albuminuria advocates other methods [7]. A positive 
dipstick result at least requires further testing.
A number of tests can help to discriminate whether 
proteinuria originates either from overﬂ   ow of serum 
proteins, glomerular damage or predominant tubulo-
interstitial damage. A simple screening test is quantitative 
urinary protein, albumin, and creatinine taken from a 
spot urine sample. Quantitative urinary protein will be 
Abstract
Renal co-morbidity is common in patients with 
rheumatic disease based on regular assessment 
of serum and urine parameters of renal function. 
When patients present with both arthritis and renal 
abnormalities the following questions have to 
be addressed. Is kidney disease a complication of 
rheumatic disease or its management, or are they 
both manifestations of a single systemic autoimmune 
disease? Is rheumatic disease a complication of kidney 
disease and its management? How do rheumatic 
disease and kidney disease aff  ect each other even 
when they are unrelated? The present review provides 
an overview of how to address these questions in daily 
practice.
© 2010 BioMed Central Ltd
Renal co-morbidity in patients with rheumatic 
diseases
Hans-Joachim Anders* and Volker Vielhauer
REVIEW
*Correspondence: hjanders@med.uni-muenchen.de
Medizinische Poliklinik, Klinikum der Universität München – Innenstadt, 
Pettenkoferstraße 8a, 80336 Munchen, Germany
Anders and Vielhauer Arthritis Research & Therapy 2011, 13:222 
http://arthritis-research.com/content/13/3/222
© 2011 BioMed Central Ltdmeasured by the salicylate method, which also detects 
immunoglobulin light chains that are missed by the 
dipstick analysis. If albuminuria accounts for most of the 
proteinuria, a glomerular disease can be anticipated. Vice 
versa, if albuminuria accounts only for a minor pro  por-
tion, the proteinuria will originate from either protein 
overﬂ  ow or tubular disease. Because urinary protein and 
albumin concentrations are confounded by ﬂ  uid intake 
and water clearance, these parameters are divided by the 
urinary creatinine concentration to calculate the urinary 
protein/creatinine ratio or the urinary albumin/creati-
nine ratio. Th  e spot urine albumin/creatinine ratio was 
already shown in 1983 to be a suitable surrogate 
parameter for the 24-hour urine protein excretion [8]. As 
a consequence, most institutions no longer collect 
24-hour urine levels. Several studies document the 
accuracy of this approach; for example, for monitoring 
lupus nephritis [9,10].
Th   e kidney has more functions beyond toxin excretion 
and ﬁ  ltration – for example, salt and water homeostasis, 
acid–base balance, and hormone production. As such, an 
elevated blood pressure and edema suggest renal sodium 
retention with or without serum creatinine elevations. 
For example, a high blood pressure and edema may be 
the ﬁ  rst clinical signs in a patient with nephrotic syn-
drome due to lupus nephritis, membranoproliferative 
GN in cryoglobulinemia or nonsteroidal anti-inﬂ  amma  tory 
drug (NSAID)-induced minimal change disease. Th  e 
kidney produces three important regulators of homeo-
stasis: renin, erythropoietin, and activated vitamin D. 
Regarding the latter, low serum calcium and elevated 
serum phosphorus must be recognized as a manifestation 
of CKD (that is, secondary hyperparathyroidism). Together, 
routine assessment should include serum creatinine with 
the estimated GFR, electrolytes, urine dipstick analysis, 
and blood pressure in all patients. Th  e urinary protein/
creatinine ratio or the urinary albumin/creatinine ratio, 
blood urea nitrogen, uric acid, cystatin C, serum bicar  bo-
nate, hemoglobin, serum calcium, phosphorus, and intact 
parathyroid hormone (iPTH) levels need to be monitored 
in CKD patients. Whether or not a kidney biopsy is 
required should be discussed with a nephrologist.
Renal and rheumatic manifestations of systemic 
autoimmune disease
Rheumatic diseases are systemic autoimmune diseases 
that preferentially aﬀ  ect joints and soft tissues, but the 
inﬂ   ammatory process regularly involves solid organs, 
including the kidney (Table 3). In addition, toxicity of 
disease-modifying antirheumatic drugs (DMARDs) 
frequently aﬀ  ects the kidney. Th  e attending specialist is 
left with the dilemma of these diﬀ  erential diagnoses that 
require either intensifying or reducing drug therapy 
(Table 2).
Rheumatoid arthritis
Owing to their high prevalence, RA and renal disease 
often coincide. Th   e renal toxicity of antirheumatic drugs 
(for example, NSAID or cyclosporine toxicity), secondary 
renal disease induced by the chronic inﬂ  ammatory 
process (especially renal amyloidosis) and, potentially, 
renal manifestations of the primary disease process, 
however, are important diﬀ  erential diagnoses.
In a prospective study of renal disease in 235 patients 
with early RA, 7% developed persistent proteinuria and 
6% presented elevated serum creatinine with or without 
Table 1. Renal functions and related clinical or laboratory parameters
Function  Clinical or laboratory parameter
Excretion  Serum levels of creatinine, blood urea nitrogen, uric acid
Filtration barrier  Proteinuria as determined by dipstick test and/or by urinary protein/creatinine ratio, urinary albumin/creatinine ratio
  Hematuria as determined by dipstick test and/or microscopy
Sodium balance  Blood pressure and edema to be evaluated by clinical examination
Water balance  Serum sodium concentration, serum osmolarity
Acid–base status  Serum bicarbonate (and chloride) concentration
Renal hormones  Erythropoietin: hemoglobin level
 1,25-(OH)2 vitamin D: serum calcium/phosphorus
 Concentrations,  iPTH
iPTH, intact parathyroid hormone.
Table 2. Renal toxicities of drugs commonly used by 
rheumatologists
Renal manifestation  Drug
Acute renal failure  NSAIDs, cyclosporine overdose, 
 biphosphonates
Chronic renal failure  NSAIDs, cyclosporine overdose
Proteinuria/nephrotic syndrome  NSAIDs, gold
Sodium retention/edema/hypertension  NSAIDs
Arterial hypertension  Lefl  unomide, cyclosporine
NSAID, nonsteroidal anti-infl  ammatory drug.
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Th   ese abnormalities were mostly drug-related and 
reversible after discontinuation of the treatment. d-
Penicillamine and gold (but not methotrexate) were most 
often associated with proteinuria. Drug-induced protein-
uria was associated with age over 50 years and elevation 
of C-reactive protein levels or the erythrocyte sedi  men-
tation rate. Seventeen percent of patients displayed 
microhematuria at study entry, with intermittent or 
persistent hematuria occurring in 42% of patients during 
the study period. Hematuria was again more common in 
patients older than 50 years and was associated with RA 
activity rather than treatment [11].
In the more recent Methotrexate and Renal Insuﬃ   -
ciency (MATRIX) study, elevated serum creatinine values 
were found in 19% of prevalent RA patients. Among 
these, 20% were in stage 2 and 15% were in stage 3 of 
CKD. Proteinuria, hematuria and leucocyturia were ob-
served in 16%, 17% and 20% of the patients, respectively 
[12]. Th   e causes of renal pathology were not determined 
in this study. In 1995, however, Helin and colleagues 
reported a retrospective analysis of renal biopsies from 
110 RA patients in whom the clinical renal disease was 
probably due to antirheumatic therapy or RA itself [13]. 
Th   e most common histopathologic ﬁ  nding was mesangial 
GN in 36%, followed by amyloidosis (30%) and mem-
branous GN (17%). Focal proliferative GN (4%), minimal-
change nephropathy (3%), and acute interstitial nephritis 
(1%) were less common. Amyloidosis was the most 
frequent ﬁ  nding in patients with nephrotic syndrome. In 
patients with isolated proteinuria, amyloidosis, mem-
branous GN, and mesangial GN were almost equally 
common [13]. Similar results were reported in 1998 from 
Japan [14]. Novel DMARDs including biological drugs 
are more eﬀ  ective in suppressing systemic inﬂ  ammation, 
however, and the incidence of renal amyloidosis has 
therefore declined [15]. Whether mesangial GN, which 
was frequently characterized by hematuria and glo-
merular deposition of IgM-containing immune com-
plexes, is directly related to RA is still a matter for debate. 
In contrast, rheumatoid vasculitis, a rare but severe 
complication of chronic, erosive RA, may directly aﬀ  ect 
the kidneys. Th   is vasculitis causes a necrotizing immune 
complex GN that requires intense immunosuppression 
[16,17].
Regardless of the etiology, concurrent renal disease is a 
predictor of mortality in RA patients. Compared with 
controls the hazard ratio for mortality was 1.78 in one 
population-based cohort study from Finland [18]. In this 
study, nephropathy presenting with combined hematuria 
and proteinuria, proteinuria alone, microalbuminuria, or 
histologically conﬁ  rmed amyloidosis was associated with 
increased mortality in RA patients, whereas mortality 
was within expected limits in those with isolated 
hematuria or mesangial GN [18].
Spondyloarthritis and psoriatic arthritis
Th  irty-ﬁ  ve percent of patients with ankylosing spondylitis 
display abnormal serum creatinine measurements or 
urinalyses, often resulting from glomerular deposition of 
amyloid A or IgA [19]. Drug-induced nephrotoxicities – 
for example, interstitial nephritis or NSAID-associated 
membranous GN – are important diﬀ  erential diagnoses 
that deserve diﬀ  erent therapeutic approaches. Amyloid-
A nephro  pathy requires aggressive control of the under-
lying rheumatic disease, whereas NSAID-induced inter-
stitial nephritis or membranous GN requires cessation of 
these drugs. In the latter case, glucocorticoids or TNF-
blocking biologicals are alternative options for 
antiphlogistic therapy, and acetaminophen, metamizol/
Table 3. Renal manifestations of systemic diseases commonly seen by rheumatologists
Disease Renal  manifestation
Rheumatoid arthritis  Mesangial GN, renal amyloidosis, membranous GN
Spondylarthropathy/psoriasis arthritis  Renal amyloidosis, IgA nephropathy
Systemic lupus erythematosus  Lupus nephritis: proliferative immune complex GN, membranous GN
Sjögren’s syndrome  Interstitial nephritis with renal tubular acidosis (type 1)
ANCA vasculitis  Crescentic (pauci-immune) GN, interstitial nephritis
Giant cell arteritis  Renal artery stenosis
Immune complex disease  Immune complex GN
Diff  use cutaneous systemic scleroderma  Scleroderma renal crisis, crescentic GN (with myeloperoxidase ANCA), interstitial nephritis, chronic (ischemic) 
 kidney  disease
Sarcoidosis  Nephrocalcinosis, nephrolithiasis, granulomatous interstitial nephritis
Malignancy  Nephrotic syndrome (membranous GN, minimal change disease, focal glomerulosclerosis)
Diabetes  Chronic kidney disease: diabetic nephropathy
Hypertension  Chronic kidney disease: hypertensive nephropathy
ANCA, anti-neutrophil cytoplasmic antibody; GN, glomerulonephritis.
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analgesic medications. Importantly, amyloid-A nephro-
pathy and NSAID-induced mem  branous GN may both 
present through nephrotic syndrome, requiring a renal 
biopsy to make a diagnosis. Patients with psoriatic 
arthritis and other spondyloarthritides (for example, 
reactive arthritis) may also present with IgA nephropathy 
or amyloid-A nephropathy. In psoriatic arthritis patients, 
elevation of serum creatinine values and/or proteinuria 
correlates with age, disease activity and duration [20].
Systemic lupus erythematosus
Lupus nephritis determines long-term morbidity and 
mortality in SLE because renal failure is associated with a 
large number of secondary and tertiary complications, as 
discussed in detail below. Lupus nephritis aﬀ  ects up to 
50% of patients with SLE, and screening SLE patients for 
renal manifestations of lupus is therefore mandatory at 
each visit. Screen  ing intervals might be longer in patients 
with discoid lupus because they experience lupus 
nephritis in less than 5% of cases [21]. No reliable 
biomarker can predict the development of lupus nephritis 
in a non-nephritic patient to date, but the presence of 
U1snRNP antibodies, C1q antibodies, inherited comple-
ment deﬁ  ciencies or high levels of anti-dsDNA antibodies 
are associated with a higher prevalence of nephritis in 
SLE patients.
Lupus nephritis can range from mild immune complex 
disease to diﬀ  use proliferative GN as classiﬁ  ed by the 
current International Society of Nephrology (ISN)/Renal 
Pthology Society (RPS) classiﬁ   cation [22]. Immune 
complex deposition within the mesangium mainly 
activates mesangial cells and causes mesangioproliferative 
GN with hematuria and various degrees of proteinuria. 
Th   e severity of renal disease correlates with the extent of 
immune complex deposits inside the glomerular mesan-
gium and capillary network (ISN/RPS classes 1 to 4). 
When lupus immune complexes deposit outside the 
glomerular basement membrane, they mainly activate 
podocytes and cause large-scale proteinuria; that is, 
nephrotic syndrome (ISN/RPS class 5), which can occur 
together with any of the other classes. ISN/RPS class 6 
represents glomerulo  sclerosis, a postinﬂ  ammatory state 
of ﬁ  brotic scaring secondary to lupus nephritis without 
major inﬂ   ammatory disease activity. Additional para-
meters indicate activity and chronicity of the lesions 
which may provide important clues for individual treat-
ment strategies [22].
Th   ere are three main reasons that argue for performing 
a renal biopsy in SLE patients with abnormal urinalysis. 
First, several studies document that ISN/RPS class 3 and 
class 4 lupus nephritis can be present in patients with 
only minor urine abnormalities, such as microhematuria 
or a protein/creatinine ratio of 0.2 to 0.5 [23]. Second, 
only ISN/RPS classes 3 to 5 with relevant disease activity 
are at risk for developing renal failure and might beneﬁ  t 
from immunosuppressive therapy. As such, a renal biopsy 
may not be needed to conﬁ  rm the diagnosis of lupus 
nephritis, but to enforce mandatory therapy despite side 
eﬀ   ects. On the contrary, unnecessary treatments are 
avoided when biopsy results indicate renal involvement 
with low inﬂ   ammatory activity. Rheumatologists (and 
nephrologists) have to ask the pathologist to provide all 
necessary information included in the ISN/RPS 
classiﬁ   cation of lupus nephritis, especially the lupus 
activity index and chronicity index. Th   is information will 
be provided by specialized renal pathologists. Th  ird,  SLE 
patients may suﬀ  er from kidney diseases other than lupus 
nephritis [23]; for example, interstitial nephritis or 
thrombotic microangiopathy as a manifestation of anti-
phospholid antibody syndrome.
Other immune complex diseases
Arthritis and nephritis are also common in other types of 
immune complex diseases such as postinfectious immune 
complex disease, Henoch–Schönlein purpura, cyroglobu-
linemia or endocarditis. While the latter example has its 
own diagnostic and treatment algorithms, all other types 
of immune complex disease may beneﬁ  t from a renal 
biopsy, because the standard histological work-up of the 
obtained renal tissue often provides diagnostic clues to 
the underlying systemic disease. Examples include endo-
capillary GN in postinfectious immune complex disease, 
IgA nephropathy in Henoch–Schönlein purpura, and 
membranoproliferative GN in cyroglobulinemia.
Anti-neutrophil cytoplasmic antibody-associated vasculitis
ANCA-associated vasculitis involves the glomerular 
capillaries leading to GN in up to 80% of Wegener’s 
patients. Abnormal serum creatinine/cystatin C levels and 
urinalysis indicate renal involvement. Urine micro  scopy 
displays dysmorphic erythrocytes, acanthocytes, and 
erythrocyte casts as a sign of destructive GN. On renal 
biopsy, ANCA-associated vasculitis typically pre  sents as a 
pauci-immune (devoid of immune complexes), necro  tiz  ing 
and crescentic GN – which is why renal ANCA-associated 
vasculitis often presents as a rapid progressive disease with 
advanced stage of renal failure. Immunosuppressive 
therapy with cyclophosphamide and glucocorticoids must 
be initiated the same day to preserve renal function [24,25]. 
In addition, patients with end-stage renal disease should be 
treated with plasma  pheresis to improve outcome [26].
Panarteriitis nodosa and giant cell arteriitis
Vasculitic involvement of intermediate-sized and large 
vessels in panarteriitis nodosa and giant cell arteriitis, 
respectively, may occasionally lead to renal functional 
impairment [27,28]. Inﬂ   ammation and formation of 
Anders and Vielhauer Arthritis Research & Therapy 2011, 13:222 
http://arthritis-research.com/content/13/3/222
Page 4 of 10micro  aneurysms in arteries of the renal parenchyma in 
panarteriitis nodosa or vasculitic stenosis of renal arteries 
and their branches in giant cell arteriitis will lead to 
chronic renal hypoperfusion and ischemia. Without 
involvement of the small glomerular capillaries these 
present clinically as progressive renal impairment and 
albuminuria, usually without gross hematuria and leuko-
cyturia on urinalysis. Imaging studies rather than renal 
biopsy are required to conﬁ  rm the diagnosis.
Scleroderma
Scleroderma can be complicated by a number of diﬀ  erent 
forms of kidney disease [29]. Th   e classical manifestation 
is scleroderma renal crisis, which represents a form of 
malignant hypertension with acute renal failure and 
potentially other organ manifestations due to excessive 
hypertension. Hypertensive crisis develops because the 
microvascular abnormalities in scleroderma cause renal 
hypoperfusion, triggering excessive release of renin that 
activates angiotensin. Immediate angiotensin blockade is 
therefore necessary. Renal crisis is an intriguing compli-
cation of diﬀ  use cutaneous systemic sclerosis but aﬀ  ects 
only 2% of patients. Many more patients have ischemic 
nephropathy leading to slowly progressing CKD that is 
accompanied by hypertension and albuminuria. Blood 
pressure measurement and dipstick analysis are therefore 
mandatory at all routine check-ups of scleroderma 
patients. Normo  tensive acute renal failure should be 
evaluated for interstitial nephritis or ANCA vasculitis, a 
separate entity in scleroderma with poor outcome [30]. A 
renal biopsy is usually required to obtain the diagnosis in 
scleroderma patients with renal failure.
Sarcoidosis
Ectopic production of calcitriol, mainly by activated 
macrophages, causes hyperabsorption of dietary calcium 
in up to 50% of patients with sarcoidosis [31]. Th  is  excess 
calcium load leads to hypercalcuria, and in 2 to 20% of 
cases leads to hypercalcemia. Th  e increased urinary 
excre  tion of calcium may cause nephrolithiasis, nephro-
calci  nosis, and polyuria. Nephrolithiasis has been re-
ported in up to 14% of patients with sarcoidosis and may 
be the initial presenting feature of as well as the cause for 
renal failure in sarcoidosis patients [31,32]. Granulo-
matous interstitial nephritis is another typical renal 
manifestation of active diﬀ  use sarcoidosis [33]. In this 
renal disease, urinalysis can be either normal or show 
sterile leukocyturia or mild tubular proteinuria that res-
ponds to glucocorticosteroids [33]. Sarcoidosis-related 
glomerular diseases are rare and their linking mecha-
nisms are unknown [34]. A nephritic sediment with 
erythro  cyte casts or heavy proteinuria should 
diﬀ   erentiate these from interstitial nephritis, although 
the diagnosis will be obtained by renal biopsy only.
Renal and rheumatic manifestations of other 
systemic diseases
Paraneoplastic syndromes
A variety of renal and musculoskeletal disorders can be 
associated with malignancy. Both types of disorder may 
occur concomitantly in individual patients, and diﬀ  er  en-
tial diagnosis may be diﬃ   cult, especially with regard to 
systemic autoimmune disease. Membranous GN, mini-
mal change nephropathy and focal glomerulo  sclerosis are 
the most common renal manifestations of malignant 
tumors [35]. Th  e predominant clinical ﬁ  nding in these 
conditions will be proteinuria with or without elevated 
serum creatinine. More rarely, membranoproliferative 
GN, rapid progressive GN, thrombotic microangiopathy, 
and interstitial renal disease have been described in 
isolated patients with solid tumors or hematologic malig-
nancies. Th   ese paraneoplastic conditions may additionally 
be accompanied by tumor-associated arthralgias, oligo-
arthritis or polyarthritis, polymyalgia and dermato-
myositis. More rarely, lupus-like syndromes, vasculitis 
and eosinophilic fasciitis may develop due to an under-
lying malignancy [36].
Establishing the correct diagnosis of a paraneoplastic 
syndrome rather than a systemic autoimmune disease with 
renal and rheumatic manifestation may be diﬃ   cult, but is 
obviously of crucial importance for the patient’s treatment 
and prognosis. Th  ese paraneoplastic syn  dromes must be 
diﬀ   erentiated from disease that directly results from 
malignancy. For example, multiple myeloma may cause 
renal damage due to amyloidosis, glomerular light/heavy 
chain deposition disease or cast nephropathy, as well as 
musculoskeletal pain due to local tumor growth. In addition, 
tumor lysis syndrome can cause uric acid nephro  pathy as 
well as crystal arthropathy. Finally, end-stage renal disease 
and proteinuria cause an elevated erythrocyte sedimen-
tation rate, which should not be suspected as active 
rheumatic disease or occult malig  nancy [37,38].
Diabetes mellitus
Diabetic nephropathy is the most common cause of end-
stage renal disease in the western world. Glomerular 
sclerosis due to chronic hyperglycemia leads to protein-
uria up to the nephrotic range, and is paralleled by a 
progressive rise in serum creatinine values. Diabetes may 
also cause musculoskeletal disorders, including diabetic 
cheiroarthropathy of the hands, and neuropathic Charcot 
arthropathy aﬀ  ecting the feet [39]. Other musculoskeletal 
complications seen in diabetic patients are Dupuytren’s 
contracture and carpal tunnel syndrome, although in 
end-stage renal disease the latter may also be caused by 
dialysis-related amyloidosis due to local deposition of β2-
microglobulin (see below). Adhesive capsulitis of the 
shoulder and diﬀ  use idiopathic skeletal hyperostosis are 
also associated with diabetes [39].
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Mineral and bone disorders are a central complication of 
CKD (referred to as CKD-MBD), because renal failure 
impairs renal phosphorus clearance and the activation of 
25-OH vitamin D. Th   e resulting hyperphosphatemia and 
hypocalcemia both induce secondary hyperpara  thyroid-
ism, which is associated with two major consequences: 
bone mineral loss and extraosseous calciﬁ  cations. 
Parathyroid hormone-induced bone mineral loss (that is, 
renal osteodystrophy) is often associated with osteo-
porosis due to immobilization during hemodialysis and 
due to CKD-associated systemic inﬂ  ammation.  Both 
increase the risk of fracture-related morbidity [40].
Th  e most common complication of CKD-MBD is 
accelerated atherosclerosis leading to cardiovascular and 
cerebrovascular events. Extravascular calciﬁ  cations  in 
CKD-MBD also include chondrocalcinosis and pseudo-
gout due to the precipitation of calcium pyro  phosphate 
dihydrate crystals. Th  e international Kidney Disease 
Improving Global Outcomes initiative guidelines are 
available for evidence-based CKD-MBD management 
and inform about the use of vitamin D analogs, phos-
phate binders, and calcium supplements [40]. Th  e 
impaired renal uric acid clearance leads to hyperuricemia. 
Concomitant use of diuretics and/or cyclosporin is 
common and can further impair uric acid clearance and 
increase the risk of gout attacks. Advanced CKD repre-
sents a state of systemic immunosuppression that can 
alter the clinical presentation of autoinﬂ  ammatory 
diseases like gout. Acute gout attacks can be mitigated in 
CKD, and symptomatic patients should be examined for 
signs of chronic gout [41]. Treating crystal arthropathy is 
problematic in CKD as drugs commonly used to treat 
acute gout attacks, such as NSAIDs, should be avoided in 
CKD patients (Table 4). Colchicine should also be 
avoided because the narrow therapeutic range makes 
appropriate dose adjustments diﬃ   cult [41]. We use 20 mg 
prednisolone for 3 to 5 days to control acute gout attacks 
and advise patients to start steroids immediately upon 
ﬁ  rst symptoms of an attack. Th   e central role of IL-1β in 
the pathophysiology of crystal arthritis suggests that IL-1 
inhibitors are eﬃ   cient in CKD patients [42,43]. Interval 
control of hyperuricemia and the treatment of chronic 
gout require dose adjustments of allopurinol or benzbro-
marone (when GFR >50  ml/minute/1.73  m2). Some 
reports propose febuxostat, uricase or anakinra as alter-
native treatments for gout, which may oﬀ  er advantages 
for CKD patients [41,43,44].
Carpal tunnel syndrome, bone cysts, and destructive 
spondyloarthropathy or joint arthropathy used to be 
classical complications for end-stage kidney disease 
patients aﬀ  ected by dialysis-related amyloidosis, but their 
prevalence declined upon broad use of high-ﬂ  ux dialysers 
[45]. Impaired clearance of small proteins like 
β2-microglobulin leads to β-sheet amyloid ﬁ  brils. 
Symptomatic amyloidosis rarely developed before 5 years 
of hemodialysis but the use of high-ﬂ  ux dialysis ﬁ  lters has 
recently delayed the onset of dialysis-related amyloidosis. 
β2-Microglobulin amyloid deposition in bone, joints, and 
tendons causes pain, stiﬀ  ness, and arthritis. Bone cysts 
can cause fractures and tendon deposits cause tears in 
ligaments and tendons [45].
Implications of unrelated chronic kidney disease in 
the rheumatic patient
Patients with impaired renal function have a substantial 
increase in cardiovascular risk that can be explained only 
in part by an increase in traditional risk factors such as 
hypertension and diabetes. It is now well recognized that 
CKD alone is an independent risk factor for cardio-
vascular complications [46,47]. International guidelines 
thus stress the need for preventing and treating 
cardiovascular risk factors in patients with CKD, as has 
been proposed for RA or SLE patients [48-51]. It is very 
likely that patients with rheumatic diseases and conco-
mitant CKD are threatened by additive proathero  genic 
eﬀ  ects, and such individuals should hence be regarded as 
high-risk patients for cardiovascular compli  ca  tions that 
deserve rigorous control of their rheumatic disease 
activity. Several DMARDs cannot be used in CKD 
patients, however, due to their inherent nephro  toxicity. 
For example, NSAIDs (including cyclooxy  genase-2 
inhibi  tors) can cause acute deterioration of renal 
function, which is more common particularly in older 
patients, in CKD patients or in heart failure patients, and 
in states of volume depletion, because renal blood ﬂ  ow is 
dependent on renal prostaglandin synthesis [52,53]. 
Glucocorticoids, acetamino  phen, metamizol/dipyrone or 
opioids can replace NSAIDs in CKD patients. Cyclo-
sporine A is another potentially nephrotoxic DMARD. 
Cyclosporine causes vasoconstriction of the aﬀ  erent and 
eﬀ  erent glomerular arterioles, which leads to reductions 
in renal blood ﬂ  ow and the GFR. Chronic administration 
of cyclosporine can cause obliterative arteriolopathy, 
ischemic scarring, tubular atrophy and progressive loss of 
renal function. Risk factors include high dose, increased 
age and pre-existing CKD [54]. Cyclosporine is hence 
contraindicated in RA patients with renal dysfunction 
according to international guidelines [55,56].
Renal insuﬃ   ciency also impairs the excretion of some 
DMARDs, which increases (nonrenal) toxicity. For 
example, metho  trexate is not nephrotoxic per se but it is 
excreted via the kidneys, and therefore accumulates and 
is increasingly toxic along the stages of CKD [57,58]. 
Some authors advocate dose reductions in CKD patients, 
but this can be dangerous because declines in the GFR 
can always happen with incident ﬂ   uid losses – for 
example, through vomiting, diarrhea, use of diuretics or 
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methotrexate clearance without a physician even being 
consulted. In view of the potential lethal side eﬀ  ects and 
usually available alternative treatment regimens (for 
example, leﬂ   unomide or biologicals), metho  trexate 
should generally be avoided in CKD patients. 
Antimalarials, sulfasalazine, and azathioprine are only 
partially excreted by the kidneys, and therefore dose 
reductions were proposed at GFR <50 ml/minute (for 
details see [59,60]).
Some DMARDs have speciﬁ  c side eﬀ  ects that add to 
the cardiovascular risk of patients with rheumatic 
disease. For example, cyclosporine or leﬂ  unomide often 
increases blood pressure, which adds blood pressure 
monitoring and blood pressure control (<130/80 mmHg) 
to the responsibilities of the rheumatologist [49]. A 
typical side eﬀ   ect of tacrolimus and tocilizumab is 
hyperlipoproteinemia, which must be controlled by 
appropriate lipid-lowering therapy to levels below 70 to 
100 mg/dl in rheumatic patients with CKD, most 
commonly with statins [48].
Anemia in patients with active rheumatic disease and 
renal insuﬃ   ciency can be inﬂ  ammation related and/or 
CKD related. Diﬀ  erential diagnosis may be diﬃ   cult in 
individual patients, but persistent anemia despite control 
of inﬂ  ammatory disease activity suggests a renal cause. 
Th   ese patients should receive iron supplementation and 
erythropoiesis-stimulating agents according to current 
guidelines [61].
It is also of note that the guidelines for the prevention 
of glucocorticoid-induced osteoporosis – that is, supple-
men  tation of calcium and vitamin D or biphosphonate 
therapy – are not validated and therefore do not apply to 
rheumatic patients with CKD. Bone metabolism in CKD 
patients is totally diﬀ  erent from that in nonrenal patients 
with its own needs for prophylaxis and therapeutic 
interventions. In addition, the use of biphosphonates is 
mostly contraindicated in the CKD patient as it can 
increase the risk of adynamic bone disease and the risk of 
biphosphonate-associated nephrotoxicity [62].
Finally, diagnostic procedures such as computed 
tomography or magnetic resonance imaging involving 
iodine-containing or gadolinium-containing contrast 
agents, respectively, must be used with great caution in 
CKD patients of stage 4 and stage 5. Radiocontrast agents 
often cause radiocontrast nephropathy that is associated 
with an increase of overall mortality, especially in CKD 
patients. If not avoidable, preventive measures such as 
discontinuation of diuretics and prehydration are man-
datory to minimize the risk of radiocontrast nephropathy 
[63]. Th  e potential beneﬁ   ts of prophylactic N-acetyl-
cysteine for the prevention of radiocontrast nephropathy 
remain under debate. Nephrogenic systemic ﬁ  brosis is a 
rare but devastating complication in patients with end-
stage renal disease that may develop after administration 
of linear gadolinium chelate-containing contrast agents 
[64]. An active inﬂ   ammatory process at the time of 
gadolinium exposure is an important risk factor for the 
subsequent development of this condition. Magnetic 
resonance imaging using linear gadolinium chelates of 
patients with active rheumatic disease and end-stage 
renal disease must therefore be avoided, and cyclic 
gadolinium chelates may be preferred in stage 4 CKD 
patients.
Conclusion
Patients with rheumatic diseases must be routinely 
monitored by blood and urinary parameters for 
Table 4. Treatment of crystal arthropathies in chronic kidney disease and dialysis patients
    CKD stage 3 and stage 4 patients  Dialysis patients
Drug  (GFR 15 to 59 ml/minute/1.73 m2)  (GFR <15 ml/minute/1.73 m2)
Pain control in acute gout attack
  NSAIDs  Avoid when possible or use with great caution  May be used with caution
  Colchicine  Avoid when possible or use with great caution (for example,   Avoid whenever possible
    0.5 mg three times per week)
  Glucocorticoids  Short-term use possible (for example, 20 mg/day)  Short-term use possible (for example, 20 mg/day)
 Anakinra  Eff  ective (100 mg/day for 3 days) but yet limited data published  Not evaluated
Maintenance therapy
  Allopurinol  Reduce dose to 100 to 150 mg or avoid  Avoid 
  Colchicine  Avoid when possible or use with great caution (for example,   Avoid whenever possible
    0.5 mg three times per week)
 Anakinra  Not  evaluated  Eff  ective in case reports (100 mg three times per week)
  Febuxostat  Safe at GFR >30 ml/minute/1.73 m2 Not  evaluated
 Benzbromarone  Probably  ineff  ective at GFR <50 ml/minute  Ineff  ective
CKD, chronic kidney disease; GFR, glomerular fi  ltration rate; NSAID, nonsteroidal anti-infl  ammatory drug.
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the same systemic disease, a side eﬀ   ect of DMARD 
therapy, or an unrelated renal disease (Figure 1). All three 
entities aﬀ  ect the diagnostic and therapeutic strategies of 
the rheumato  lo  gist. It should therefore be left to the 
expertise of the nephrologist to determine whether renal 
biopsy is required for the diagnostic work-up. Patients 
should be subdivided into those needing more intense 
immunosuppressive treat  ment because of their kidney 
disease and those needing dose reduction or modiﬁ  cation 
of their medication because of their kidney disease. 
Ideally, patients with rheumatic diseases and renal co-
morbidity should be managed through close colla-
boration between a rheuma  tologist and a nephrologist.
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